Inhibrx Biosciences’ INBRX-106 combination produced a 48.3% confirmed response rate in Phase 2 HNSCC, versus 26.5% for pembrolizumab alone. The results support expansion of the randomized study, planned FDA alignment and a Phase 3 confirmatory trial, while additional 2027 lung-cancer data could broaden development.
Key Highlights
- HPV-positive patients recorded an 80.0% confirmed response rate with the combination versus 33.3% for pembrolizumab monotherapy.
- Inhibrx plans to expand the HexAgon Phase 2 study and pursue a Phase 3 confirmatory trial.
- Median progression-free survival was 9.6 months with the combination versus 4.9 months with pembrolizumab alone.
Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported a 48.3% confirmed objective response rate for INBRX-106 plus pembrolizumab in a randomized Phase 2 HNSCC study. Pembrolizumab alone produced a 26.5% response rate, giving the combination the higher result in the primary endpoint analysis.
HexAgon Data Show Longer Progression-Free Survival
The analysis used data cut off on August 19, 2026, and showed median progression-free survival of 9.6 months for the combination versus 4.9 months for pembrolizumab alone. Six-month progression-free survival rates were 72.4% and 42.8%, respectively. Four patients, or 13.8% of those receiving the combination, achieved a complete response, compared with none in the control arm. Among patients with HPV-positive disease, confirmed response rates were 80.0% with the combination and 33.3% with pembrolizumab alone, while six-month progression-free survival was 90.0% versus 33.0%.
Inhibrx Plans Expansion and Phase 3 Testing
The company is also evaluating INBRX-106 in perioperative non-small cell lung cancer, with initial results targeted for 2027. Inhibrx plans to explore combinations with therapeutic cancer vaccines.
FAQs
Q: What were Inhibrx’s INBRX-106 Phase 2 HNSCC results?
A: The randomized Phase 2 analysis showed a 48.3% confirmed objective response rate for INBRX-106 plus pembrolizumab, compared with 26.5% for pembrolizumab alone. Four combination-arm patients achieved complete responses.
Q: How did INBRX-106 perform in HPV-positive disease?
A: In HPV-positive disease, the combination produced an 80.0% confirmed objective response rate, compared with 33.3% for pembrolizumab alone. Six-month progression-free survival was 90.0% versus 33.0%, respectively.
Q: What progression-free survival results did the Phase 2 study report?
A: Median progression-free survival was 9.6 months with the combination and 4.9 months with pembrolizumab alone. Six-month progression-free survival rates were 72.4% and 42.8%, respectively.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.